Alzamend Neuro (ALZN) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NeuroSense Therapeutics is the larger company by market cap ($6.9 million vs $6.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALZN | NRSN |
|---|---|---|
| Share price | $1.34 | $3.66 |
| Market cap | $6.47M | $6.94M |
| 1-day change | 0.00% | -2.14% |
| EPS (TTM) | $-2.30 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.68 | $26.64 |
| 52-week low | $0.84 | $3.56 |
| Distance from 52-week high | -50.00% | -86.26% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1840.30% | +2559.29% |
| Average volume | 88.67K | 21.29K |
| Shares outstanding | 4.83M | 1.90M |
| Employees | 4 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alzamend Neuro
ALZN stock →Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
ALZN vs NRSN FAQ
Which is bigger, Alzamend Neuro or NeuroSense Therapeutics?
NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $6.94M compared with $6.47M for Alzamend Neuro (ALZN).
Are Alzamend Neuro and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.